In CRND8 APP transgenic mice (TgCRND8) model of AD, NLRP3 inhibitor JC-124 administration (50 mg/kg/day, five times per week for four consecutive weeks) significantly reduces number of Iba-1+ microglia/macrophages and Aβ deposition, although, it does not alter the number of GFAP + astrocytes in the brain (Yin et al., 2018). This evidence concerns the gene GFAP and Alzheimer disease.